A monoclonal antibody was raised against the major capsid protein LI of human papillomavirus type 16, using a recombinant vaccinia virus that expresses the LI protein, as a target for screening. This antibody, designated CAMVIR-1, reacted with a 56 kilodalton protein in cells infected with LI-vaccinia virus, and the protein was present in a predominantly nuclear location. The antibody also detects the HPV-16 Li antigen in formalin fixed, paraffin wax embedded biopsy specimens and on routine cervical smears. The antibody reacts strongly and consistently with biopsy specimens containing HPV-16 or HPV-33, but very weak reactions were occasionally observed with biopsy specimens or smears containing HPV-6 or HPV-1.
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The potential advantages of using a vaccinia recombinant are (i) the target protein is synthesised in a eukoryotic cell so that its "processing" and location are normal; (ii) cells infected with vaccinia recombinants can be subjected to various fixing procedures similar to those used for routine clinical material. This greatly increases the probability that an identified antibody will be useful in a clinical setting.
subjects. The ubiquity of viral DNA highlights the need for reagents that will detect viral proteins. Several groups have recently tried to overcome the problems associated with the lack of a permissive in vitro culture system by cloning and expressing viral genes in prokaryotic and eukaryotic expression systems." '2 In an earlier paper we reported the construction of a vaccinia virus recombinant containing the HPV 16 Li gene (encoding the major capsid antigen), and the preparation of polyclonal antisera raised against a bacterial fusion protein containing HPV 16 LI sequences.'3 Polyclonal antisera, however, are of limited use in that they cannot give information about the presence of type specific epitopes on the LI protein and tend to result in high background in immunohistochemical and immunoprecipitation studies. There is a need for type specific reagents for diagnostic as well as for research purposes for viruses such as HPV 16 , which has been identified in 50-600/o of cases of cervical carcinoma subjected to viral typing. 5 In this report we describe the production of a monoclonal antibody to HPV 16 L1 using a novel protocol in which viral antigen is generated for immunisation using a bacterial expression system and hybridoma supernants are screened for specific antibody using a vaccinia recombinant expressing the target protein. CTIONS DNA was present at low copy number but it :t the LI was not possible to determine which type. In wax em-two cases where positive staining with led using CAMVIR-1 was observed a very high copy staining number of HPV-1 1 was present (more than 106 from the genomic copies a cell). In three cases hybridisabnts with tion showed the presence ofHPV-16 DNA, but a routine no staining with CAMVIR-1 was observed n. These because the smear was inadequate. presence ie culture Discussion 10. Figure The absence of a suitable in vitro system for the of several propagation of human papillomaviruses, tostrongly gether with the fact that in clinical lesions only hology of very low levels of virus are present, has necesesion was sitated the use of alternative strategies for the establish production of immunological reagents to these (fig 2b) . viruses. In the production of monoclonal antiumber of bodies suitable targets for the screening of region of hybridoma fluids are an important requireprotein-ment. To date, the monoclonal antibodies esion. We reported have been raised and screened against ions (n = bacterial derived proteins.'6"8 We used cells iing with infected with a vaccinia virus recombinant Lybridisa-expressing the HPV 16 LI open reading frame HPV-16 as a target for the selection of monoclonal The op-antibodies. This system provided a very conis, a min-venient and plentiful source of viral protein, !-16 by in free of potentially crossreactive bacterial ning with elements. md that a
The antibody against the HPV-16 LI pro- served among the different HPV types, and there is one amino acid substitution between HPV16 and HPV-6 or -11 in this region, namely, D to N (GFGAMNF), which would explain the weak cross reactivity with these virus types. CAMVIR-1 identifies an epitope on HPV-1 6 LI that is strongly reactive against HPV-16 and -33 and, to a much lesser extent, with HPV-6 and -11, and thus is able to identify a subgroup of human papillomaviruses with malignant oncogenic potential.
Expression of the L1 capsid protein, as identified with this monoclonal antibody, is strongly focal, and in any one lesion only a few cells with high copy viral DNA synthesise LI protein. This situation differs from that seen in some other lesions induced by papillomavirus, particularly cutaneous warts'9 and bovine papillomas20 in which many cells express viral capsid proteins and in which viral particles are present in substantial numbers. The focality of Li expression in the cervical lesions may be related to the paucity of viral particles in lesions containing HPV 16. Alternatively, it may be related to the stage of infection at which the cervical lesion has been biopsied. The natural history of HPV-16 related disease is virtually unknown. It is evident from studies on other papillomaviruses, particularly CRPV and BPV-1, that the development of a lesion in which viral capsid protein and viral particles are produced requires a considerable time period-of the order of months.2' Anecdotal evidence in human disease suggests that a similar time period is involved in the development of genital condylomata."2 In many patients biopsy specimens may be taken at a stage in the natural history of the disease when viral particles are not produced, either because the lesion is at an early stage or because a quiescent or persistent phase is another feature of the disease process. Whatever the explanation it is evident that L1 capsid protein is synthesised in a few cells containing high numbers of viral DNA copies in the superficial, terminally differentiated surface layers of the epithelium.
Detection of viral DNA only informs about presence of the genome and gives little information on virus replication and pathogenesis. This is particularly important in that papillomaviruses are strictly epitheliotropic, and the available information indicates that permissive viral replication only occurs in keratinocytes and specifically in the keratinocyte undergoing the normal process of differentiation in the epithelium. The intra-epithelial neoplastic lesions of the cervix are characterised by a progressive loss and distortion of the normal differentiation process, and these features are included in the diagnostic criteria of these lesions.2" Changes in the expression of viral proteins may be a reflection of neoplastic phenotype and may give useful information on progression and prognosis, and the antibody CAMVIR-1 may be a useful reagent in this 
